There’s no doubting which direction Boston Scientific sees healthcare going as the cardiovascular device company acquires a significant shareholding in diagnostic and monitoring company Preventice Solutions.
Cardiac monitoring is a critical component required for the diagnosis of many arrhythmias that require clinical intervention. Add to this a remote monitoring capability and you have the bones of an infrastructure that will form an integral part of delivering cost-effective healthcare for the future.
Preventice Solutions is a leading developer of mobile health solutions and services, offering a full portfolio of wearable cardiac monitors, including Holter monitors, cardiac event monitors and mobile cardiac telemetry. These technologies are complemented by monitoring services including data transmission, surveillance, reporting, interpretation and integration into a healthcare provider’s workflow. Alongside its equity investment, Boston Scientific will become the exclusive worldwide sales and marketing representative for Preventice’s cardiology-related offerings.
From Boston Scientific’s perspective this move will see it vertically integrating itself into the cardiac healthcare continuum, bringing in Preventice’s wireless monitoring portfolio linked to an integrated remote monitoring platform. The cardiac diagnostics and monitoring market is already valued at an estimated $1Bn and is sure to expand.
Capability-wise, Boston will have made sure it was backing the right horse, finding in Preventice a company with an an infrastructure optimized to monitor hundreds of thousands of patients each year.
“As our healthcare environment continues to evolve, healthcare practitioners, administrators and payors are looking for solutions that identify relevant clinical insights from large volumes of patient data and integrate those insights to improve clinical decision-making,” said Joe Fitzgerald, executive vice president and president, Rhythm Management, Boston Scientific.
Source: PR Newswire